21 Nov

Laura Hamilton to become CEO of North America for HealthBeacon

Laura Hamilton to become CEO of North America for HealthBeacon

Nov 21ST 2019, Dublin, Ireland and Boston Headquartered, HealthBeacon, a leading global medical adherence technology provider whose mission is to “build smart tools for managing medications” will be establishing a dedicated North American division to drive the development of its business and technology platform across the USA and Canada.

It’s FDA cleared “best in class” medical adherence tool for tracking injectable medications has already been launched in 13 countries and has tracked over 300,000 Injections in patient’s homes, globally. At the recent Connected Health Conference in Boston, HealthBeacon published peer-reviewed evidence demonstrating the ability for patients to successfully adopt their technology as a result of patient-centered design.  The platform has been designed to improve long term adherence to medication regimes and provide critical health data back to clinicians.

HealthBeacon’s Boston office can be described as just “Off Broadway” located above the CVS pharmacy on West Broadway in South Boston. Their Boston office has full business development, technical operations and customer care capabilities which are integrated into clinical systems, research organisations, and pharmaceutical patient support programs.

In her role as CEO of North America, Laura will be responsible for developing both the market and the HealthBeacon organisation across this important region and will report into Co-Founder and CEO, Jim Joyce.

I first got to know Laura over 4 years ago in her time as Director of Business Development of the Massachusetts Biotechnology Council (MassBio) and in her capacity as President of BIBA (Boston Irish Business Association). She is a high energy, talented leader and we couldn’t be more excited to welcome her into the company at such an exciting time.Jim Joyce, CEO and Co-Founder, HealthBeacon.

Upon joining the company this week, Laura stated, “I am delighted to be joining HealthBeacon as CEO of North America, based at the US Headquarters in Boston, MA. I’ve been closely connected to the company for many years and truly admire the leadership, the team they’ve developed, as well as the early successes they’ve achieved across Europe. The business is poised for tremendous growth in North America and is creating value in the healthcare ecosystem with their world leading technology, which tracks patient adherence to injectable medications for chronic disease. I’m so looking forward to getting started and joining the team of one of Ireland’s most innovative start-ups.

MassBio President & CEO Robert Coughlin added, “The convergence between digital health and the life sciences is creating incredible opportunities to transform patient care. With Laura joining the team, I am excited to watch HealthBeacon grow in Massachusetts and beyond as it advances solutions to improve health outcomes.

Laura most recently served as Executive Vice President, US Operations for RxCelerate, an outsourced drug discovery and drug development platform company based in Cambridge UK. Prior to that role, Laura was Director of Business Development at MassBio. She is a proud three-time graduate of Northeastern University in Boston with a BSBA in Finance, Masters Degree in Innovation (MSc) and Master of Business Administration (MBA). A native of Cork, Ireland, Laura is currently the President of the Boston Irish Business Association (BIBA) and also serves on the Board of Directors at the American Heart Association – Metro Boston.

Laura Hamilton HealthBeacon’s CEO of North America

HealthBeacon Boston Office

13 Nov

The Impact of Connected Devices on Medication Adherence

Sean Glynn, M.S., is the Director of HEOR and Strategic Initiatives for HealthBeacon in North America

Zara Fullerton Kinsella, Medical Doctor, is the Medical Science Liaison for HealthBeacon

A physician recently described an interaction where a patient was ending a course of therapy due to a poor response to treatment. The patient asked, “What should I do with the leftover medication I have at home?”  The doctor replied, “I thought you said you were taking all of your medication.  Why do you have leftover medication?”

This is not an isolated event. One out of every two patients fail to take their medication as directed and have stopped treatment within a twelve-month period. For those of us familiar with the medication non-adherence problem, this is not surprising. Hippocrates was known to have said, “Keep a watch also on the faults of the patients, which often make them lie about the taking of things prescribed.”

Our generation is asking for connected devices to be a positive force for change in every aspect of health support, and adherence is no exception. The health and technology industries are making multi-billion dollar investments so that connected devices can fundamentally transform the delivery of healthcare. Technology offers a wide variety of solutions from smart packaging to robotic dispensers, the Internet of Things offers connected devices that monitor when medicine is unpackaged and even when a used needle is disposed into a smart sharps container. Mobile technology can remind and reward patients to help them stay on track with their medication and software platforms convey, synthesize and prioritize cohort data for clinicians. In addition, artificial intelligence can offer insights into big data and predict required interventions before a patient becomes symptomatic.

Getting health data from patients has challenged the industry to innovate. Our approach at HealthBeacon has been to use the Internet of Things to passively track what the patient is already doing, in this case, disposing of a used pen or syringe into a sharps container. By capturing this behavior and relaying the information to patients, caregivers and physicians, a key data point is created. This collection of data on a real-time basis can serve to increase patient engagement, lead to more informed clinical decision making and ultimately enable the early identification of patients who may benefit from interventions that focus on improving adherence.

If this patient had been in possession of an adherence monitoring device, their story would have been very different. Any missed doses of medication would have immediately been identified and shared with their healthcare provider or caregiver, enabling them to receive the support they need to maximize outcomes from their treatment.

Connected devices have the potential to identify and support those patients who need the most help with managing their medication. Given the magnitude of this group, these technologies have a transformative role to play in improving patient care and enriching the relationship between physicians, patients and caregivers.

Media enquiries: Mary Principe  | Email: events@healthbeacon.com

13 Nov

HealthBeacon appoints Sean Glynn as first Director of HEOR, and Dr. Zara Fullerton Kinsella as first Medical Science Liaison

HealthBeacon appoints first Director of HEOR and hires first Medical Science Liaison.

(Dublin, Ireland; Boston, MA, – November 13th, 2019) Leading medication adherence technology company, HealthBeacon has announced the appointments of Sean Glynn as Director of Health Economics and Outcomes Research, and Dr. Zara Fullerton Kinsella as Medical Science Liaison.

Sean Glynn, Director of HEOR, joined the HealthBeacon team three years ago with the critical role of launching HealthBeacon’s operations in the US. Sean’s background in behavioral sciences and his deep understanding of the medication adherence issue will be instrumental in furthering HealthBeacon’s mission to improve patient outcomes by delivering new adherence solutions to patient’s who self-administer injectable medications in their homes. Sean is based out of HealthBeacon’s Boston office.

Dr. Zara Fullerton Kinsella has joined the HealthBeacon team as a Medical Science Liaison, to facilitate clinical research and assist with Regulatory Affairs. Zara is a medical doctor with an undergraduate degree in Business and Economics at Trinity College. Her keen interest in healthcare led her to study Graduate Entry Medicine at University College Cork. As a junior doctor, she worked in a variety of medical specialties. Zara is based out of HealthBeacon’s office in Dublin, Ireland.

These appointments will further HealthBeacon’s commitment to evidence-based decision making and program design. “We are excited to expand our team and add these critical capabilities with Sean being promoted to Director of HEOR and Dr. Zara joining the team as our Medical Science Liaison” said Jim Joyce, CEO of HealthBeacon, “these roles will bring through our latest studies, data projects and provide important medical insights into product development.”

About HealthBeacon

HealthBeacon is a medication adherence technology company which develops smart tools for managing medication at home. HealthBeacon’s FDA cleared smart sharps bin tracks patient injection history, provides personalized interactive reminders and safely stores used injectables. With the intervention of HealthBeacon’s Smart Sharps Technology, patients’ persistence and adherence increased by 25-30% within twelve months of initiating therapy. The HealthBeacon integrated model connects a patient’s routine and the prescribing clinician’s workflow. This technology has been adopted across thirteen countries with >300,000 injections tracked since launch in 2014, with a patient acceptance rate of
80-90%.

 

HealthBeacon’s Medical Science Liaison Dr. Zara Fullerton Kinsella

HealthBeacon’s HEOR Sean Glynn

Media Enquiries: Mary Principe  | Email: events@healthbeacon.com